A team of American researchers has been able to prevent accumulation in the brain of toxic proteins that cause Alzheimer's. Tests have been done so far on laboratory mice, but can soon be tested on humans, according to RTE. The new vaccine contains DNA encoding a segment of the betamyloid protein building block. In the study, the vaccine triggered an immune response that not only resulted in a 40% decrease in beta amyloid formation, but also decreased your protein formation by 50%. The research was conducted on mice that were genetically engineered to develop a rodent equivalent of Alzheimer's disease, says adevarul.ro.
"This study is the result of a decade of research that has repeatedly shown that this vaccine can reliably and reliably identify in animal models what we think can cause Alzheimer's disease," says Dr. Roger Rosenberg, Head of the team, of the center of Alzheimer's, University of Texas, cited by Agerpres.ro. "I think we are approaching to test this therapy for humans," he said. An important barrier to the development of effective anti-Alzheimer vaccines has been to find ways to introduce them into the body.
A previous experimental vaccine, developed in the early 2000s, caused some brain tumors in some patients when tested on humans. The new vaccine is injected into the skin instead of the muscle, which leads to another type of immune response. If the effects observed in mice will be repeated in humans, this vaccine would have a "high therapeutic value," said the researchers. "If the disease could be postponed for five years, it would be huge for patients and their families," co-authors Doris Lambracht-Washington, another member of the University of Texas team, studies. "The number of dementia could decrease by half," he said. A number of drugs targeted at cerebral amyloid protein stores and you develop or test clinically. But an effective vaccine would be a better strategy, according to researchers at the University of Texas. It would be cheaper and cheaper. Earlier this year, the same research team found the exact point where a molecule becomes harmful but has not yet formed "crowds" in the brain.
The researchers also work with a spinal fluid test that can detect your abnormal protein before the symptoms of the disease occur. Such a test can identify people who have not yet had symptoms but who have high levels of tau and amyloid in the brain. Patients identified by this test may then be candidates for treatment with the vaccine. "The more you wait, the less it will have. Once these boards and branches have been formed, it may be too late," explained Dr. Rosenberg. The results of the research were published in Alzheimer's research and therapy. So far, it is known that two types of toxic proteins play a key role in the development of Alzheimer's beta-amyloid disease and yours. Beta-amyloid and your brain accumulate in the brain and cause the destruction of nerve cells. Some studies indicate that the two are linked, beta-amyloid that favors the formation of "agglomerations" caused by your protein.